News and events

A recent research has highlighted a groundbreaking discovery concerning the connection between HMGB1 released by mesothelial cells and the development of asbestos-induced mesothelioma.

Liam Colley, HMGBiotech’s researcher, gave a speech about “The role of CXCR4 in Triggering Immunosurveillance in the Malignant Mesothelioma Tumor Environment”.

HMGB1 has been shown to play a key role in Parkinson’s disease pathogenesis. Research and studies targeting High Mobility Group Box 1 (HMGB1) protein in Parkinson’s disease (PD) has recently emerged, with promising results in the inhibition of HMGB1.

Recent studies showed HMGB1’s role in the fight against cancer. HMGB1 is increasingly associated with tumor stages, prognosis, immune response and drug resistance.

Latest researches showed that HMGB1 is involved in causing ischemic stroke by ehnancing inflammation and tissue damage in cerebrovascular diseases.

HMGBiotech specializes in the production of LPS-free proteins. LPS (Bacterial endotoxin lipopolysaccharide) is a powerful inducer of the immune system and can introduce undesirable variables and limitations in certain experimental setups.

A recent paper published on Molecular Medicine journal highlights how High Mobility Group Box 1 (HMGB1) and other biomolecules influence fatigue in patients with Crohn’s diseases.

HMGBiotech Srl has taken part to a study, published in June, in which are discovered CXCL12 as the first fuzzy chemokines heterocomplex reported so far and the unexpected role of the acidic intrinsically disordered region (IDR), in HMGB1●CXCL12 heterocomplex formation.

A new research, in which HMGBiotech Srl participated, has unmasked an unexpected player in the world of chemokine interactions: the acidic intrinsically disordered region (IDR).